CDH3 and breast carcinoma: Additionally, it is also interesting to note that, although the BS2 mutation did not create a significant decrease in CDH3 promoter activity in MCF-7/AZ cells, this binding site is important to LAP2-mediated activation, indicating that it may not be endogenously active in these breast cancer cells, but probably highly active in BT-20 cells.